OpenCareby Vivonco
Search/
Talk to us Review a case
Menu
Skip to content
No. 40 · Wednesday, November 18, 2026

Trial did not prove partial-breast radiation matches whole-breast treatment for breast cancer

  1. Trial did not prove partial-breast radiation matches whole-breast treatment for breast cancer
  2. Immunotherapy before surgery was feasible for resectable liver cancer
  3. Blood immune pattern linked to treatment response in cervical cancer
  4. Atlas maps immune features linked to skin cancer outcomes
  5. Tumor protein patterns linked to immunotherapy response in metastatic skin cancer
  6. Blood test predicted recurrence in head and neck cancer
  7. TIGIT marker identifies tumor-reactive cells in skin cancer blood
Read this first · Phase III trial · breast cancer

Trial did not prove partial-breast radiation matches whole-breast treatment for breast cancer

In a trial of people with low-risk breast cancer, partial-breast radiation led to cancer returning in 1.0% of patients at five years, compared with 0.8% after whole-breast radiation. The trial did not prove the treatments were equally effective.

“Although formal statistical noninferiority was not demonstrated because the upper confidence limit crossed the margin, the absolute difference was <0.2%.”

Why it matters. People with low-risk breast cancer may have partial-breast radiation as an alternative to treating the whole breast. Results from a large final-stage trial like this decide approvals.

Journal of Clinical Oncology, 17 Nov 2026 · Phase III human clinical trial | 3,309 patients Worth sharing · Share on X · Email a friend
Phase I trial · liver cancer

Immunotherapy before surgery was feasible for resectable liver cancer

In a phase 1b trial, people with early-stage liver cancer that could be removed received the immunotherapies nivolumab and ipilimumab before surgery. The approach was feasible, but larger trials are needed to confirm its benefit.

“Longitudinal circulating tumour DNA (tumour DNA found in the blood) monitoring could support detection of minimal residual disease (traces of cancer left after treatment) and warrants further prospective validation.”

Why it matters. People with early-stage liver cancer that can be removed may be able to get immunotherapy before surgery. This early safety trial is years from routine use.

The Lancet Oncology, 17 Nov 2026 · Phase I human clinical trial
Phase I/II trial · cervical cancer

Blood immune pattern linked to treatment response in cervical cancer

In 29 people with advanced cervical cancer, researchers found that a blood immune pattern was linked to better outcomes with the immunotherapies durvalumab and tremelimumab plus vinorelbine chemotherapy. Clinical benefit was 76% in people with more of the pattern, versus 25% in others.

Why it matters. A blood test for this immune pattern may help doctors identify people with cervical cancer more likely to benefit from this treatment. This early safety trial is years from routine use.

Cancer Immunology Research, 17 Nov 2026 · Phase I/II human clinical trial
Research · melanoma, a skin cancer

Atlas maps immune features linked to skin cancer outcomes

Researchers analyzed 183 skin cancers using many types of molecular data. Tumor antigens tracked with immune cell presence, while other protein and sugar changes were linked to survival differences.

Why it matters. People with skin cancer may one day get treatment choices guided by tumor features linked to immune response and survival. It studied patient records rather than testing a treatment.

Cancer Discovery, 17 Nov 2026 · Human observational study
Research · melanoma, a skin cancer

Tumor protein patterns linked to immunotherapy response in metastatic skin cancer

Researchers studied tumor samples from 164 people with metastatic skin cancer treated with combined immunotherapy. In one study group, the protein-defined group with the highest response rate had 74% respond, compared with 44% in the group with the lowest rate.

“A clinically tractable 127-protein classifier provides a foundation for prospective biomarker-driven combination immunotherapy (treatment that helps the immune system fight cancer) trials.”

Why it matters. People with metastatic skin cancer may one day have treatment choices guided by protein patterns in their tumors. It studied patient records rather than testing a treatment.

Clinical Cancer Research, 17 Nov 2026 · Human observational study
Research · head and neck cancer

Blood test predicted recurrence in head and neck cancer

Researchers studied people treated with chemoradiotherapy for head and neck cancer. At 12 weeks, the blood test found 69% of recurrences and correctly ruled out recurrence in 100% of people without it.

“Plasma-only methylation-based circulating tumour DNA provided high-specificity (how often the test correctly rules cancer out) prognostic information after definitive CRT in LA-HNSCC, particularly at week 12 and in PET partial-responders. circulating tumour DNA may complement PET/CT for post-treatment risk stratification, but should not be used as a stand-alone test to exclude recurrence.”

Why it matters. People treated for head and neck cancer may get extra information about recurrence risk from a blood test alongside scans. It studied patient records rather than testing a treatment.

Clinical Cancer Research, 17 Nov 2026 · Human observational study
Research · melanoma, a skin cancer

TIGIT marker identifies tumor-reactive cells in skin cancer blood

Researchers studied blood from people with melanoma and found that TIGIT marked immune cells that attacked their tumors, detecting more tumor-reactive cells than PD-1 alone. These cells were more common in people who responded to immune checkpoint treatment.

“Collectively, our data establish TIGIT⁺ CD8⁺ T cells as a potent reservoir of tumor-reactive T cells in peripheral blood and provide a blood-based framework for accelerating TCR discovery and advancing adoptive cell therapy.”

Why it matters. People with skin cancer may benefit from blood tests that help doctors track tumor-reactive immune cells and guide personalized treatment. It studied patient records rather than testing a treatment.

Cancer Immunology Research, 17 Nov 2026 · Human observational study

Deals and stopped trials

India

New trials

Worth watching